CY1119367T1 - Παραγοντες προσδεσης του psma και χρησεις αυτων - Google Patents
Παραγοντες προσδεσης του psma και χρησεις αυτωνInfo
- Publication number
- CY1119367T1 CY1119367T1 CY20171100825T CY171100825T CY1119367T1 CY 1119367 T1 CY1119367 T1 CY 1119367T1 CY 20171100825 T CY20171100825 T CY 20171100825T CY 171100825 T CY171100825 T CY 171100825T CY 1119367 T1 CY1119367 T1 CY 1119367T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- psma
- access factors
- tomography
- phenylhydrazine
- Prior art date
Links
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 title abstract 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 title abstract 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 239000012707 chemical precursor Substances 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical group NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 abstract 1
- 238000002600 positron emission tomography Methods 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 238000002603 single-photon emission computed tomography Methods 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/18—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/22—Tin compounds
- C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8546208P | 2008-08-01 | 2008-08-01 | |
| US11179108P | 2008-11-06 | 2008-11-06 | |
| PCT/US2009/052456 WO2010014933A2 (en) | 2008-08-01 | 2009-07-31 | Psma-binding agents and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119367T1 true CY1119367T1 (el) | 2018-02-14 |
Family
ID=41610978
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100825T CY1119367T1 (el) | 2008-08-01 | 2017-07-31 | Παραγοντες προσδεσης του psma και χρησεις αυτων |
| CY20221100403T CY1125468T1 (el) | 2008-08-01 | 2022-06-09 | Παραγοντες προσδεσης toy psma και χρησεις αυτων |
| CY2023024C CY2023024I2 (el) | 2008-08-01 | 2023-11-03 | Παραγοντες προσδεσης του psma και χρησεις αυτων |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20221100403T CY1125468T1 (el) | 2008-08-01 | 2022-06-09 | Παραγοντες προσδεσης toy psma και χρησεις αυτων |
| CY2023024C CY2023024I2 (el) | 2008-08-01 | 2023-11-03 | Παραγοντες προσδεσης του psma και χρησεις αυτων |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US8778305B2 (enExample) |
| EP (3) | EP4089074A1 (enExample) |
| JP (6) | JP5588441B2 (enExample) |
| KR (1) | KR101664855B1 (enExample) |
| CN (3) | CN107382846B (enExample) |
| AU (1) | AU2009276423B2 (enExample) |
| CA (2) | CA2987744C (enExample) |
| CY (3) | CY1119367T1 (enExample) |
| DK (2) | DK2318366T3 (enExample) |
| ES (2) | ES2634894T3 (enExample) |
| FI (1) | FIC20230033I1 (enExample) |
| FR (1) | FR23C1044I2 (enExample) |
| HK (1) | HK1247197A1 (enExample) |
| HR (2) | HRP20220742T1 (enExample) |
| HU (3) | HUE059436T2 (enExample) |
| LT (3) | LT3222615T (enExample) |
| LU (1) | LUC00323I2 (enExample) |
| NL (1) | NL301250I2 (enExample) |
| NO (1) | NO2024006I1 (enExample) |
| PL (2) | PL3222615T3 (enExample) |
| PT (2) | PT3222615T (enExample) |
| RU (1) | RU2494096C2 (enExample) |
| SI (2) | SI2318366T1 (enExample) |
| SM (1) | SMT201700371T1 (enExample) |
| WO (1) | WO2010014933A2 (enExample) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2187965T3 (da) | 2007-08-17 | 2020-01-20 | Purdue Research Foundation | Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse |
| US9422234B2 (en) * | 2007-11-30 | 2016-08-23 | The Johns Hopkins University | Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer |
| WO2009084995A1 (en) | 2007-12-28 | 2009-07-09 | Exini Diagnostics Ab | System for detecting bone cancer metastases |
| ES2634894T3 (es) * | 2008-08-01 | 2017-09-29 | The Johns Hopkins University | Agentes de unión a PSMA y usos de los mismos |
| CA2769444A1 (en) | 2009-05-19 | 2010-11-25 | Aic Blab Company | Composite current collector and methods therefor |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| US10011632B2 (en) | 2011-08-22 | 2018-07-03 | Siemens Medical Solutions Usa, Inc. | PSMA imaging agents |
| US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
| EP2785712B1 (en) | 2011-11-30 | 2019-05-01 | The Johns Hopkins University | Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (pmsa) and uses thereof |
| US20140065070A1 (en) * | 2012-08-28 | 2014-03-06 | Mcmaster University | Methods of preparing triazole-containing radioiodinated compounds |
| KR102318999B1 (ko) * | 2012-11-15 | 2021-10-29 | 엔도사이트, 인코포레이티드 | Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트 |
| SMT202300035T1 (it) * | 2013-03-15 | 2023-05-12 | Cancer Targeted Tech Llc | Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi |
| WO2015057692A1 (en) | 2013-10-14 | 2015-04-23 | The Johns Hopkins University | Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy |
| AU2014336638C1 (en) | 2013-10-18 | 2020-09-17 | Novartis Ag | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| JP6292568B2 (ja) * | 2013-11-06 | 2018-03-14 | 国立大学法人京都大学 | ウレア誘導体化合物、これを含有する放射性医薬 |
| WO2015073678A1 (en) | 2013-11-14 | 2015-05-21 | Endocyte, Inc. | Compounds for positron emission tomography |
| US9713649B2 (en) | 2014-01-24 | 2017-07-25 | The Cleveland Clinic Foundation | PSMA-targeting imaging agents |
| US10556916B2 (en) * | 2014-04-01 | 2020-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Zirconium-89 oxine complex as a cell labeling agent for positron emission tomography |
| EP2993171A1 (en) * | 2014-09-04 | 2016-03-09 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the production of 18F-labeled PSMA-specific PET-tracers |
| US10112974B2 (en) | 2014-08-24 | 2018-10-30 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer |
| EP3011976A1 (en) * | 2014-10-20 | 2016-04-27 | Deutsches Krebsforschungszentrum | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents |
| EP3209336B1 (en) * | 2014-10-20 | 2019-12-11 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| WO2016065142A2 (en) * | 2014-10-22 | 2016-04-28 | The Johns Hopkins University | New scaffolds and multifunctional intermediates for imaging psma and cancer therapy |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| US20180338910A1 (en) * | 2015-01-09 | 2018-11-29 | The Johns Hopkins University | Intranasal administration of glutamate carboxypeptidase (gcp-ii) inhibitors |
| US10869940B2 (en) | 2015-06-12 | 2020-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted photoacoustic compounds, formulations, and uses thereof |
| US20180236109A1 (en) * | 2015-08-20 | 2018-08-23 | Universitat Zu Koln | Pain Tracking by PET-imaging (Pain-TraP) |
| PL3356385T3 (pl) | 2015-09-30 | 2021-06-28 | Deutsches Krebsforschungszentrum | Tagowane 18F inhibitory antygenu błonowego specyficznego dla gruczołu krokowego (PSMA) i ich zastosowanie jako środków do obrazowania w nowotworze gruczołu krokowego |
| WO2017070482A2 (en) * | 2015-10-22 | 2017-04-27 | The Johns Hopkins University | Psma targeted radiohalogenated ureas for cancer radiotherapy |
| KR101639599B1 (ko) | 2015-11-09 | 2016-07-14 | 서울대학교산학협력단 | 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물 |
| EP3400229B1 (en) | 2016-01-10 | 2024-03-06 | Provincial Health Services Authority | 18/19f-labelled compounds which target the prostate specific membrane antigen |
| DK3481804T3 (da) * | 2016-06-10 | 2025-01-13 | Univ Johns Hopkins | Forbedret syntese af radioaktivt mærket hæmmer af prostataspecifikt membranantigen (PSMA) [18F]DCFPyL |
| SG11201811482YA (en) * | 2016-06-23 | 2019-01-30 | Univ Cornell | Double targeted constructs to affect tumor kill |
| US10806806B2 (en) | 2016-06-23 | 2020-10-20 | Cornell University | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies |
| EP4636783A3 (en) | 2016-10-27 | 2025-12-24 | Progenics Pharmaceuticals, Inc. | Network for medical image analysis, decision support system, and related graphical user interface (gui) applications |
| WO2018090976A1 (zh) * | 2016-11-17 | 2018-05-24 | 思路迪（北京）医药科技有限公司 | 一种具有抗癌作用的化合物及其制备方法和应用 |
| DE102016122273B4 (de) * | 2016-11-18 | 2018-06-21 | Abx Advanced Biochemical Compounds Gmbh | Präkursoren für die Radiofluorierung |
| KR102724812B1 (ko) | 2017-04-05 | 2024-11-01 | 코넬 유니버시티 | 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물 |
| MX2019012017A (es) | 2017-04-07 | 2020-02-12 | Juno Therapeutics Inc | Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados. |
| JP7373998B2 (ja) | 2017-05-02 | 2023-11-06 | コーネル・ユニバーシティー | 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬 |
| WO2018236115A1 (ko) | 2017-06-19 | 2018-12-27 | (주)퓨쳐켐 | 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도 |
| HRP20220557T1 (hr) | 2017-06-19 | 2022-06-10 | Futurechem Co., Ltd. | Spoj obilježen s 18f namijenjen dijagnosticiranju raka, te njegova upotreba |
| JP2021500373A (ja) | 2017-10-23 | 2021-01-07 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 線維芽細胞活性化タンパク質α（ＦＡＰ−α）を標的とする撮像剤および放射線療法用薬剤 |
| DK3723815T3 (da) * | 2017-12-11 | 2022-07-11 | Univ Muenchen Tech | PSMA ligander til billeddannelse og endoradioterapi |
| ES3026214T3 (en) | 2018-01-08 | 2025-06-10 | Progenics Pharm Inc | System and method for rapid neural network-based image segmentation |
| US12602772B2 (en) | 2018-01-08 | 2026-04-14 | Progenics Pharmaceuticals, Inc. | Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination |
| US10973486B2 (en) | 2018-01-08 | 2021-04-13 | Progenics Pharmaceuticals, Inc. | Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination |
| WO2019157037A1 (en) * | 2018-02-06 | 2019-08-15 | The Johns Hopkins University | Psma targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy |
| WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
| MX2020010813A (es) | 2018-04-17 | 2021-01-08 | Endocyte Inc | Metodos de tratamiento de cancer. |
| CN109160899B (zh) * | 2018-05-16 | 2021-06-04 | 上海如絮生物科技有限公司 | 一种亲水性吡啶类化合物、中间体、其制备方法及应用 |
| CN109160896B (zh) * | 2018-05-16 | 2021-06-25 | 上海如絮生物科技有限公司 | 一种亲水性吡啶类化合物中间体及其制备方法 |
| CN109160898B (zh) * | 2018-05-16 | 2021-06-04 | 上海如絮生物科技有限公司 | 一种亲水性吡啶类化合物中间体及其制备方法 |
| US20210338846A1 (en) * | 2018-07-30 | 2021-11-04 | The Johns Hopkins University | Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy |
| CN113164450A (zh) | 2018-10-11 | 2021-07-23 | 普罗热尼奇制药公司 | 用于治疗转移性前列腺癌的组合治疗 |
| RU2697519C1 (ru) * | 2018-10-15 | 2019-08-15 | Общество с ограниченной ответственностью "Изварино Фарма" | Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом |
| KR102403970B1 (ko) | 2018-12-27 | 2022-05-31 | (주)퓨쳐켐 | 카르복시산이 도입된 psma-표적 화합물 및 그의 용도 |
| JP7568628B2 (ja) | 2019-01-07 | 2024-10-16 | エクシーニ ディアグノスティクス アーべー | プラットホーム非依存の全身画像セグメント化のためのシステムおよび方法 |
| PL239934B1 (pl) * | 2019-04-12 | 2022-01-31 | Narodowe Centrum Badan Jadrowych Osrodek Radioizotopow Polatom | Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty |
| CA3136979A1 (en) | 2019-04-17 | 2020-10-22 | Provincial Health Services Authority | Radiolabelled compounds for diagnosis or treatment of prostate-spe cific membrane antigen-expressing cancer |
| CA3136127A1 (en) | 2019-04-24 | 2020-10-29 | Progenics Pharmaceuticals, Inc. | Systems and methods for automated and interactive analysis of bone scan images for detection of metastases |
| CN113748443B (zh) | 2019-04-24 | 2025-09-09 | 普罗热尼奇制药公司 | 用于交互式调整核医学图像中的强度窗口设定的系统和方法 |
| EP3972627A4 (en) | 2019-05-20 | 2023-06-21 | Endocyte, Inc. | Methods for preparing psma conjugates |
| WO2020252598A1 (en) | 2019-06-21 | 2020-12-24 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| RU2713151C1 (ru) * | 2019-07-02 | 2020-02-04 | Общество с ограниченной ответственностью "Изварино Фарма" | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения |
| US12582728B2 (en) | 2019-08-30 | 2026-03-24 | Memorial Sloan Kettering Cancer Center | Theranostic agents for PSMA positive cancers |
| US11900597B2 (en) | 2019-09-27 | 2024-02-13 | Progenics Pharmaceuticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
| US11564621B2 (en) | 2019-09-27 | 2023-01-31 | Progenies Pharmacenticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
| US12417533B2 (en) | 2019-09-27 | 2025-09-16 | Progenics Pharmaceuticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
| US11544407B1 (en) | 2019-09-27 | 2023-01-03 | Progenics Pharmaceuticals, Inc. | Systems and methods for secure cloud-based medical image upload and processing |
| KR102269315B1 (ko) | 2019-10-24 | 2021-06-24 | 서울대학교산학협력단 | 전립선 암의 영상 또는 치료를 위한 동위원소 표지 화합물 |
| US11321844B2 (en) | 2020-04-23 | 2022-05-03 | Exini Diagnostics Ab | Systems and methods for deep-learning-based segmentation of composite images |
| US11386988B2 (en) | 2020-04-23 | 2022-07-12 | Exini Diagnostics Ab | Systems and methods for deep-learning-based segmentation of composite images |
| CN111548305B (zh) * | 2020-05-12 | 2021-08-31 | 北京师范大学 | 一种可用于靶向psma的喹啉类化合物及其制备方法 |
| TWI920110B (zh) | 2020-07-06 | 2026-04-01 | 瑞典商艾西尼診斷公司 | 用於偵測及表徵化病變之基於人工智慧的影像分析系統與方法 |
| US11721428B2 (en) | 2020-07-06 | 2023-08-08 | Exini Diagnostics Ab | Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions |
| EP4244216A1 (en) | 2020-11-12 | 2023-09-20 | ABX Advanced Biochemical Compounds GmbH | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
| WO2022106629A1 (en) | 2020-11-19 | 2022-05-27 | Novartis Ag | Synthesis of prostate specific membrane antigen (psma) ligands |
| CN114685599A (zh) * | 2020-12-30 | 2022-07-01 | 南京江原安迪科正电子研究发展有限公司 | 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途 |
| EP4378948A4 (en) | 2021-07-30 | 2026-05-20 | Univ Osaka | RADIOMARKED COMPOUND AND ITS USE |
| US12597127B2 (en) | 2021-10-08 | 2026-04-07 | Exini Diagnostics Ab | Systems and methods for automated identification and classification of lesions in local lymph and distant metastases |
| US20250332265A1 (en) | 2021-11-09 | 2025-10-30 | Case Western Reserve University | Psma targeted conjugate compounds and uses thereof |
| EP4537301A2 (en) | 2022-06-08 | 2025-04-16 | Progenics Pharmaceuticals, Inc. | Systems and methods for assessing disease burden and progression |
| IL321958A (en) | 2023-01-10 | 2025-09-01 | Sun Pharma Advanced Res Co Ltd | Ligand-drug conjugates |
| US20240285248A1 (en) | 2023-02-13 | 2024-08-29 | Progenics Pharmaceuticals, Inc. | Systems and methods for predicting biochemical progression free survival in prostate cancer patients |
| CN116217505B (zh) * | 2023-03-17 | 2024-10-01 | 南京医科大学 | 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂 |
| US20240354940A1 (en) | 2023-04-07 | 2024-10-24 | Progenics Pharmaceuticals, Inc. | Systems and methods for facilitating lesion inspection and analysis |
| EP4785275A1 (en) | 2023-09-25 | 2026-08-05 | Progenics Pharmaceuticals, Inc. | Systems and methods for automated cancer staging and risk prediction |
| WO2025090594A1 (en) * | 2023-10-25 | 2025-05-01 | The Johns Hopkins University | Deep transfer learning for fully automated tumor quantification and prognosis of cancer on pet/ct |
| DE102023133281B8 (de) * | 2023-11-28 | 2025-07-24 | Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien Gmbh | Radiotracer und Präkursoren für diese Radiotracer sowie Verwendung dieser Radiotracer als Diagnostika und Therapeutika |
| CN117670883B (zh) * | 2024-01-31 | 2024-05-07 | 中国医学科学院北京协和医院 | 一种鉴别高低级别膀胱癌的方法、设备和系统 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2233269C2 (ru) * | 1998-11-02 | 2004-07-27 | Авентис Фарма Лимитед | Замещенные анилиды, фармацевтическая композиция и способ лечения |
| JP3750494B2 (ja) | 1999-08-31 | 2006-03-01 | 松下電器産業株式会社 | 半導体装置 |
| WO2006093991A1 (en) * | 2005-03-02 | 2006-09-08 | The Cleveland Clinic Foundation | Compounds which bind psma and uses thereof |
| RU2435782C2 (ru) * | 2006-02-22 | 2011-12-10 | Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. | Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция |
| ES2684322T3 (es) * | 2006-11-08 | 2018-10-02 | Molecular Insight Pharmaceuticals, Inc. | Heterodímeros de ácido glutámico |
| WO2009002529A2 (en) * | 2007-06-26 | 2008-12-31 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
| ATE530169T1 (de) * | 2007-09-28 | 2011-11-15 | Bind Biosciences Inc | Krebszellen-targeting mit nanopartikeln |
| ES2634894T3 (es) * | 2008-08-01 | 2017-09-29 | The Johns Hopkins University | Agentes de unión a PSMA y usos de los mismos |
| GB0905438D0 (en) | 2009-03-30 | 2009-05-13 | Ge Healthcare Ltd | Radiolabelling reagents and methods |
| DK3481804T3 (da) * | 2016-06-10 | 2025-01-13 | Univ Johns Hopkins | Forbedret syntese af radioaktivt mærket hæmmer af prostataspecifikt membranantigen (PSMA) [18F]DCFPyL |
-
2009
- 2009-07-31 ES ES09803670.0T patent/ES2634894T3/es active Active
- 2009-07-31 ES ES17167057T patent/ES2914593T3/es active Active
- 2009-07-31 JP JP2011521362A patent/JP5588441B2/ja active Active
- 2009-07-31 CN CN201710536671.3A patent/CN107382846B/zh active Active
- 2009-07-31 PT PT171670573T patent/PT3222615T/pt unknown
- 2009-07-31 US US13/057,044 patent/US8778305B2/en active Active
- 2009-07-31 EP EP22163541.0A patent/EP4089074A1/en active Pending
- 2009-07-31 PT PT98036700T patent/PT2318366T/pt unknown
- 2009-07-31 PL PL17167057.3T patent/PL3222615T3/pl unknown
- 2009-07-31 SI SI200931704T patent/SI2318366T1/sl unknown
- 2009-07-31 EP EP17167057.3A patent/EP3222615B1/en active Active
- 2009-07-31 LT LTEP17167057.3T patent/LT3222615T/lt unknown
- 2009-07-31 CN CN200980139135.3A patent/CN102171187B/zh active Active
- 2009-07-31 AU AU2009276423A patent/AU2009276423B2/en active Active
- 2009-07-31 CA CA2987744A patent/CA2987744C/en active Active
- 2009-07-31 HU HUE17167057A patent/HUE059436T2/hu unknown
- 2009-07-31 DK DK09803670.0T patent/DK2318366T3/en active
- 2009-07-31 DK DK17167057.3T patent/DK3222615T3/da active
- 2009-07-31 KR KR1020117004960A patent/KR101664855B1/ko active Active
- 2009-07-31 HU HUE09803670A patent/HUE034027T2/en unknown
- 2009-07-31 HR HRP20220742TT patent/HRP20220742T1/hr unknown
- 2009-07-31 CA CA2732632A patent/CA2732632C/en active Active
- 2009-07-31 RU RU2011107752/04A patent/RU2494096C2/ru active
- 2009-07-31 LT LTEP09803670.0T patent/LT2318366T/lt unknown
- 2009-07-31 PL PL09803670T patent/PL2318366T3/pl unknown
- 2009-07-31 SM SM20170371T patent/SMT201700371T1/it unknown
- 2009-07-31 WO PCT/US2009/052456 patent/WO2010014933A2/en not_active Ceased
- 2009-07-31 EP EP09803670.0A patent/EP2318366B1/en active Active
- 2009-07-31 HR HRP20171133TT patent/HRP20171133T1/hr unknown
- 2009-07-31 CN CN202110689899.2A patent/CN113563262B/zh active Active
- 2009-07-31 SI SI200932167T patent/SI3222615T1/sl unknown
-
2012
- 2012-02-27 HK HK18106684.8A patent/HK1247197A1/zh unknown
-
2014
- 2014-03-14 US US14/211,683 patent/US9226981B2/en active Active
- 2014-07-25 JP JP2014152130A patent/JP5806765B2/ja active Active
-
2015
- 2015-09-04 JP JP2015174731A patent/JP6030724B2/ja active Active
-
2016
- 2016-01-04 US US14/987,032 patent/US9861713B2/en active Active
- 2016-10-20 JP JP2016206120A patent/JP6524046B2/ja active Active
-
2017
- 2017-07-31 CY CY20171100825T patent/CY1119367T1/el unknown
-
2018
- 2018-01-08 US US15/864,236 patent/US10500292B2/en active Active
- 2018-11-26 JP JP2018220353A patent/JP7277113B2/ja active Active
-
2019
- 2019-11-05 US US16/674,089 patent/US20200282083A1/en not_active Abandoned
-
2021
- 2021-01-28 JP JP2021012046A patent/JP7219497B2/ja active Active
- 2021-04-22 US US17/237,850 patent/US12070513B2/en active Active
-
2022
- 2022-06-09 CY CY20221100403T patent/CY1125468T1/el unknown
-
2023
- 2023-11-02 FI FIC20230033C patent/FIC20230033I1/fi unknown
- 2023-11-03 CY CY2023024C patent/CY2023024I2/el unknown
- 2023-11-06 FR FR23C1044C patent/FR23C1044I2/fr active Active
- 2023-11-14 LT LTPA2023534C patent/LTC2318366I2/lt unknown
- 2023-11-14 HU HUS2300039C patent/HUS2300039I1/hu unknown
- 2023-11-15 NL NL301250C patent/NL301250I2/nl unknown
- 2023-12-01 LU LU00323C patent/LUC00323I2/fr unknown
-
2024
- 2024-02-01 NO NO2024006C patent/NO2024006I1/no unknown
- 2024-07-15 US US18/772,628 patent/US20250177578A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125468T1 (el) | Παραγοντες προσδεσης toy psma και χρησεις αυτων | |
| Bois et al. | [68Ga] Ga-PSMA-11 in prostate cancer: a comprehensive review | |
| EA201100301A1 (ru) | Daa-пиридин в качестве лиганда периферического бензодиазепинового рецептора для диагностической визуализации и фармацевтического лечения | |
| EP3777898A3 (en) | Compounds for positron emission tomography | |
| Benfante et al. | An overview of in vitro assays of 64Cu-, 68Ga-, 125I-, and 99mTc-labelled radiopharmaceuticals using radiometric counters in the era of radiotheranostics | |
| MY188934A (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| NL1026220A1 (nl) | Stationair computertomografiesysteem met compact röntgenstralenbron-samenstel. | |
| Khosravifarsani et al. | High cytotoxic effect by combining copper-64 with a nota–terpyridine platinum conjugate | |
| Mishiro et al. | Development of radiohalogenated osimertinib derivatives as imaging probes for companion diagnostics of osimertinib | |
| Mari et al. | Applications of radiolabelled curcumin and its derivatives in medicinal chemistry | |
| WO2008024826A3 (en) | Radiohalothymidines and methods of their synthesis and use in pet imaging of cancers | |
| WO2016040458A3 (en) | Pet probes of radiofluorinated carboximidamides for ido-targeted imaging | |
| Weeks et al. | Radiobiological effects of hypoxia-dependent uptake of 64Cu-ATSM: enhanced DNA damage and cytotoxicity in hypoxic cells | |
| CY1113022T1 (el) | Ακτινoφαρμακευτικες συνθεσεις οι οποιες περιεχουν πολυσακχαριτες εμβολιασμενους με πολυαμιδια | |
| MX2009003617A (es) | Derivados de silicio para obtencion de imagenes por tomografia de emision de positrones (pet). | |
| WO2009025914A3 (en) | Radiolabelled fluorobenzamide analogues, their synthesis and use in diagnostic imaging | |
| LeBlanc | Cancer and comparative imaging | |
| Marques et al. | Radiopharmaceuticals for targeted radiotherapy | |
| Giammei et al. | Towards dual-tracer SPECT for prostate cancer imaging using [99mTc] Tc-PSMA-I&S and [111In] In-RM2 | |
| Chiotellis et al. | Synthesis and Characterization of novel “3+ 2” oxorhenium complexes, ReO [SNO][NN] | |
| ATE521591T1 (de) | 11c-markierte benzyl-lactam-verbindungen und deren verwendung als bildgebungsmittel | |
| EA200800948A1 (ru) | Биотиндиаминопроизводные и их конъюгаты с макроциклическими хелатирующими реагентами | |
| WO2011160216A3 (en) | Compounds useful in imaging and therapy | |
| CY1125591T1 (el) | Ενωσεις στοχευσης psma και χρησεις αυτων | |
| Kyrkou et al. | Development of AGT-7: An Innovative 99mTc-Labeled Theranostic Platform for Glioblastoma Imaging and Therapy |